[{"description":"Targeted (341 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"IMPACT341"},{"description":"Targeted (410 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"IMPACT410"},{"description":"Targeted (468 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"IMPACT468"},{"description":"Targeted sequencing of urcc tumor via MSK-IMPACT.","genePanelId":"IMPACT"},{"description":"Targeted (300 cancer genes) sequencing of bladder urothelial carcinomas via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"IMPACT300"},{"description":"Targeted deep sequencing (TDS) of 1202 genes on Illumina HiSeq2000 sequencers.","genePanelId":"UCLA_1202"},{"description":"Targeted sequencing of urcc tumor via MSK-IMPACT.","genePanelId":"IMPACT230"},{"description":"Targeted (27 cancer genes) sequencing of adenoid cystic carcinomas on Illumina HiSeq sequencers.","genePanelId":"ACYC_FMI_27"},{"description":"Targeted (173 cancer genes) sequencing of breast cancers on Illumina HiSeq sequencers.","genePanelId":"METABRIC_173"},{"description":"Targeted sequencing of 504 cancer-associated genes on Illumina HiSeq sequencers.","genePanelId":"DFCI_504"},{"description":"DNA sequencing of 623 genes with known or potential relationships to cancer.","genePanelId":"WUSTL-DFCI_623"},{"description":"Targeted (279 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"IMPACT279"},{"description":"Targeted sequencing of various tumor types via bait v3.","genePanelId":"bait_v3"},{"description":"Targeted sequencing of various tumor types via bait v5.","genePanelId":"bait_v5"},{"description":"Targeted sequencing of various tumor types via bait v4.","genePanelId":"bait_v4"},{"description":"Targeted NGS of NSCLC Samples.","genePanelId":"NSCLC_UNITO_2016_PANEL"},{"description":"Targeted massively parallel sequencing of 1651 cancer genes.","genePanelId":"NOVARTIS_BROAD_1651"},{"description":"Targeted panel of 387 cancer-related genes.","genePanelId":"bcc_unige_2016_cancer_panel"},{"description":"A panel that's designed to target all exons of 264 genes that are recurrently mutated in de novo MDS/AML (â??RMG reagentâ??).","genePanelId":"RMG"},{"description":"Targeted panel of 8 genes.","genePanelId":"AmpliSeq"},{"description":"Foundation Medicine T4b gene panel (214 genes)","genePanelId":"FMI-T4b"},{"description":"FoundationOne Heme gene panel targets the entire coding sequence of 406 genes, selected introns of 31 genes involved in rearrangements and utilizes RNA sequencing to interrogate 265 genes","genePanelId":"FMI-R2"},{"description":"Targeted (470 cancer genes, IMPACT468 plus MYB and NFIB) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"MYB-IMPACT468"},{"description":"Foundation Medicine T5a gene panel (323 genes)","genePanelId":"FMI-T5a"},{"description":"Foundation Medicine T7 gene panel (429 genes)","genePanelId":"FMI-T7"},{"description":"FoundationOne Heme gene panel targets the entire coding sequence of 406 genes, selected introns of 31 genes involved in rearrangements and utilizes RNA sequencing to interrogate 265 genes","genePanelId":"FMI-D2"},{"description":"Targeted (343 cancer genes, IMPACT341 plus MYB and NFIB) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"MYB-IMPACT341"},{"description":"Targeted (412 cancer genes, IMPACT410 plus MYB and NFIB) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers.","genePanelId":"MYB-IMPACT410"},{"description":"Targeted sequencing of 15 oncogenes and tumor suppressor genes, selected for their potential as predictive biomarkers of response to targeted agents by Sanger sequencing.","genePanelId":"MSKCC_BLCA_15"},{"description":"Targeted panel of 232 genes.","genePanelId":"Agilent"},{"description":"ARCHER-HEME gene panel (200 genes)","genePanelId":"ARCHER-HEME-CV1"},{"description":"ARCHER-SOLID Gene Panel (62 genes)","genePanelId":"ARCHER-SOLID-CV1"},{"description":"Targeted panel of 601 genes.","genePanelId":"gbm_tcga_pub_cancer_panel"},{"description":"Targeted (400 cancer genes) sequencing of various tumor types via MSK-IMPACT Heme on Illumina HiSeq sequencers.","genePanelId":"IMPACT-HEME-400"},{"description":"Hotspot sequencing panel for MSK-IMPACT Heme on Illumina HiSeq sequencers (204 genes).","genePanelId":"IMPACT-HEME-HS"},{"description":"Targeted panel of 137 genes.","genePanelId":"prad_mskcc_sanger"},{"description":"Targeted panel of 22 genes.","genePanelId":"prad_mskcc_sequenom"},{"description":"Targeted panel of 146 genes. (merge of prad_mskcc_sanger and prad_mskcc_sequenom)","genePanelId":"prad_mskcc_sequenom_sanger"},{"description":"Targeted sequencing of clinical cases via Thunderbolts NGS Target Enrichment System, RainDance Technologies.","genePanelId":"RDTB49"},{"description":"Targeted sequencing of clinical cases via ThunderStorm NGS Target Enrichment System, RainDance Technologies.","genePanelId":"RDTS30"},{"description":"Targeted panel of 226 protein-coding genes.","genePanelId":"sarc_mskcc_panel"},{"description":"Research (CMO) IMPACT-Heme gene panel version 3.","genePanelId":"HemePACT_v3"},{"description":"Foundation Medicine T5 gene panel (326 genes)","genePanelId":"glioma_mskcc_2019_fmi_t5"},{"description":"Foundation Medicine T7 gene panel (434 genes)","genePanelId":"glioma_mskcc_2019_fmi_t7"},{"description":"High-intensity targeted sequencing assay by GRAIL covering 508 genes.","genePanelId":"grail_cfdna_508"},{"description":"Targeted variant analysis from 73 cancer genes by Next-Generation (NGS)/Massively parallel sequencing (MPS).","genePanelId":"GUARDANT_73"}]
